Utilization of Direct Acting Oral Anticoagulants in Patients with Liver Cirrhosis: Is It Safe?

Saad Qadwai¹*, Tayyaba Rehman² and Zeeshan Solangi³

Received: June 07, 2018;   Published: June 11, 2018

DOI: 10.32474/CTGH.2018.01.000106

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Patients with liver cirrhosis are known to have increased risk bleeding particularly from gastrointestinal tract. However, recent literature has shown that patients with liver cirrhosis are also at increased risk of thrombotic complications. Therefore, it is important to consider anticoagulation in cirrhotic patients. The purpose of this article is to review the epidemiological studies available in scientific literature comparing the risk of bleeding in cirrhotic patients utilizing DOACs vs traditional anticoagulation.

Abbreviations: INR: International Normalized Ratio; VTE: Venous Thromboembolism; DVT: Deep Venous Thrombosis; PE: Pulmonary Embolism; PTT: Partial Thromboplastin Time; LMWH : Low-Molecular-Weight Heparin; NO: Nitric Oxide; PTT: Partial Thromboplastin Time; DOACs: Direct Oral Anticoagulants; AT: Antithrombin; ULN: Upper Limit Of Normal; AUC: Area Under The Plasma Concentration-Time Curve; PD pharmacodynamics; PK: pharmacokinetics

Abstract| Introduction| Methods| Results| Conclusion| References|